

Product Name: Nesbuvir Revision Date: 01/10/2021

# **Product Data Sheet**

## **Nesbuvir**

**Cat. No.:** A3655

CAS No.: 691852-58-1

Formula: C22H23FN2O5S


**M.Wt:** 446.49

Synonyms: HCV 796;HCV-796;HCV796,Nesbuvir

Target: Proteases

Pathway: HCV Protease

Storage: Store at -20°C



# Solvent & Solubility

 $\geqslant$ 22.3 mg/mL in DMSO; insoluble in H2O;  $\geqslant$ 97.8 mg/mL in EtOH with gentle warming

In Vitro

Preparing Stock Solutions	Solvent Concentration	1mg	5mg	10mg
	1 mM	2.2397 mL	11.1985 mL	22.3969 mL
	5 mM	0.4479 mL	2.2397 mL	4.4794 mL
	10 mM	0.2240 mL	1.1198 mL	2.2397 mL

Please refer to the solubility information to select the appropriate solvent.

## **Biological Activity**

Reacting conditions:

Shortsummary	NS5B polymerase inhibito	or
IC <sub>50</sub> & Target		
	Cell Viability Assay	Section 1 to the second section 1 to the section 1 to the second section 1 to the second section 1 to the second section 1 to the sectio
	Cell Line:	Huh7-BB7 cells
	Preparation method:	The solubility of this compound in DMSO is > 22.3 mg/mL. General tips for
In Vitro		obtaining a higher concentration: Please warm the tube at 37 °C for 10 minutes
		and/or shake it in the ultrasonic bath for a while. Stock solution can be stored
		below -20°C for several months.

7 d, 40-80 nM

	Applications:	Nesbuvir is an inhibitor of the hepatitis C virus (HCV) nonstructural protein 5B	
		(NS5B) polymerase. It has potent and specific inhibitory effect against the HCV	
		RdRp, thus inhibiting RNA synthesis. When Nesbuvir is used in combination	
		with boceprevir, it decreases the frequency with which resistant variants occur	
		in Huh7-BB7 cells bearing a subgenomic genotype 1b HCV replicon.	
	Animal experiment	310	
In Vivo	Animal models:	Urokinase plasminogen activator (uPA)/severe combined immunodeficient (SCID) mice	
	Dosage form:	Oral administration, 50 mg/kg, three times daily for 5 days	
	Applications:	Treating mice with Nesbuvir resulted in a 2.02 $\pm$ 0.55 log10 decrease of HCV titer with one mouse below the level of detection, whereas HCV levels in the control group of mice were relatively stable (0.26 $\pm$ 0.16 log10 decline).	
	Other notes:	Please test the solubility of all compounds indoor, and the actual solubility may slightly differ with the theoretical value. This is caused by an experimental system error and it is normal.	

### **Product Citations**

See more customer validations on www.apexbt.com.

### References

[1]. Flint M, Mullen S, Deatly A M, et al. Selection and characterization of hepatitis C virus replicons dually resistant to the polymerase and protease inhibitors HCV-796 and boceprevir (SCH 503034)[J]. Antimicrobial agents and chemotherapy, 2009, 53(2): 401-411. [2]. Kneteman N M, Howe A Y M, Gao T, et al. HCV796: a selective nonstructural protein 5B polymerase inhibitor with potent anti-hepatitis C virus activity in vitro, in mice with chimeric human livers, and in humans infected with hepatitis C virus[J]. Hepatology, 2009, 49(3): 745-752.

### **Caution**

#### FOR RESEARCH PURPOSES ONLY.

#### NOT FOR HUMAN, VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.

Specific storage and handling information for each product is indicated on the product datasheet. Most APExBIO products are stable under the recommended conditions. Products are sometimes shipped at a temperature that differs from the recommended storage temperature. Shortterm storage of many products are stable in the short-term at temperatures that differ from that required for long-term storage. We ensure that the product is shipped under conditions that will maintain the quality of the reagents. Upon receipt of the product, follow the storage recommendations on the product data sheet.

APERIC

## **APExBIO Technology**

### www.apexbt.com

7505 Fannin street, Suite 410, Houston, TX 77054.

Tel: +1-832-696-8203 | Fax: +1-832-641-3177 | Email: info@apexbt.com



APE BIO

APE BIO

APE BIO

APE BIO

APE BIO

APE BIO